SEGMENT INFORMATION (Tables)

9 Months Ended

Jul. 31, 2023

Segment Profitability and Segment Assets

The profitability of each of the segments is measured after excluding items such as transformational initiatives, acquisition and integration costs, amortization of intangible assets related to business combinations, interest income, interest expense and other items as noted in the reconciliations below:


	Three Months Ended				Nine Months Ended
	July 31,				July 31,
	2023		2022		2023		2022
	(in millions)
Net Revenue:
Life Sciences and Applied Markets	$	927	$	1,019	$	2,928	$	2,891
Diagnostics and Genomics	349		340		1,053		1,037
Agilent CrossLab	396		359		1,164		1,071
Total net revenue	$	1,672	$	1,718	$	5,145	$	4,999

Segment Income From Operations:
Life Sciences and Applied Markets	$	277	$	311	$	855	$	821
Diagnostics and Genomics	84		73		216		232
Agilent CrossLab	129		88		335		266
Total segment income from operations	$	490	$	472	$	1,406	$	1,319

The following table reflects segment and unallocated assets. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, short-term and long-term investments, deferred tax assets, right-of-use assets and other assets.


	July 31, 2023		October 31, 2022
	(in millions)
Assets:
Life Sciences and Applied Markets	$	3,924	$	3,955
Diagnostics and Genomics	3,255		3,489
Agilent CrossLab	926		869
Unallocated Assets	2,570		2,219
Total assets	$	10,675	$	10,532

Reconciliation of segment results to total enterprise results

The following table reconciles segment income from operations to Agilent’s total enterprise income before taxes:


	Three Months Ended				Nine Months Ended
	July 31,				July 31,
	2023		2022		2023		2022
	(in millions)
Total segment income from operations	$	490	$	472	$	1,406	$	1,319
Transformational initiatives	(19)		(8)		(31)		(21)
Amortization of intangible assets related to business combinations	(38)		(48)		(112)		(149)
Acquisition and integration costs	(5)		(4)		(12)		(19)
Asset impairment	(277)		—		(277)		—
Change in fair value of contingent consideration	—		—		(1)		25
Acceleration of share-based compensation expense	(5)		—		(5)		—
Business exit and divestiture costs	—		—		—		(7)


Special compliance costs	(4)		—		(9)		—
Other	(9)		(1)		(17)		(1)
Interest income	13		2		34		4
Interest expense	(24)		(19)		(73)		(61)
Other income (expense), net (1)	10		3		16		(41)
Income before taxes, as reported	$	132	$	397	$	919	$	1,049

(1) For the three and nine months ended July 31, 2023 and 2022, other income (expense), net includes net (gains) losses on the fair value of equity securities.